[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2295054A1 - Traitement de maladies autoinflammatoires a l'aide d'inhibiteurs de l'ice - Google Patents

Traitement de maladies autoinflammatoires a l'aide d'inhibiteurs de l'ice Download PDF

Info

Publication number
EP2295054A1
EP2295054A1 EP10178054A EP10178054A EP2295054A1 EP 2295054 A1 EP2295054 A1 EP 2295054A1 EP 10178054 A EP10178054 A EP 10178054A EP 10178054 A EP10178054 A EP 10178054A EP 2295054 A1 EP2295054 A1 EP 2295054A1
Authority
EP
European Patent Office
Prior art keywords
compound
subject
syndrome
ice
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10178054A
Other languages
German (de)
English (en)
Inventor
John R. Randle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of EP2295054A1 publication Critical patent/EP2295054A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Autoinflammatory diseases are a group of related conditions that include Muckle-Wells Syndrome (MWS), Familial Cold Autoinflamammatory Syndrome (FCAS) (also known as Familial Cold Urticaria or FCU), Familial Mediterranean Fever (FMF), Chronic Infantile Neurological Cutaneous and Articular Syndrome (CINCAS), a.k.a. Neonatal Onset Multisystem Inflammatory Disease (NOMID), TNFRI-Associated Periodic Syndrome (TRAPS), Hyper-IgD periodic fever Syndrome (HIDS), and Blau's syndrome ( Gumucio et al., Clin. Exp. Rheumatol. 20: S-45-S-53, 2002 ).
  • MFS Muckle-Wells Syndrome
  • FCAS Familial Cold Autoinflamammatory Syndrome
  • FMF Familial Mediterranean Fever
  • CINCAS Chronic Infantile Neurological Cutaneous and Articular Syndrome
  • NOMID Neonatal Onset Multisystem Inflammatory Disease
  • TRAPS TNFRI-Associated Periodic Syndrome
  • HIDS
  • ICE interleukin-1 ⁇ converting enzyme
  • ICE is a protease that converts the inactive precursor, pro-interleukin-1 ⁇ (pro-IL-1 ⁇ ) to the active cytokine interleukin-1 ⁇ (IL-1 ⁇ ), as well as pro-IL-18 to mature, active IL-18.
  • pro-IL-1 ⁇ pro-interleukin-1 ⁇
  • IL-1 ⁇ active cytokine interleukin-1 ⁇
  • pro-IL-18 cytokine interleukin-1 ⁇
  • CAIS1 codes for the protein cryopyrin. Mutations of this gene and alteration of cryopyrin alters ICE activation, the consequent processing of pro-IL-1 ⁇ to IL-1 ⁇ and causes MWS and FCAS ( Hoffman et al., Nat. Genet. 29: 301-305, 2001 ).
  • IL-1 ⁇ The critical role of IL-1 ⁇ in the etiology of MWS (and by inference in FCAS, FMF, CINCAS, NOMID, TRAPS, HIDS and other autoinflammatory diseases and conditions) is illustrated by the demonstration that patients with MWS respond to treatment with recombinant human interleukin-1 receptor antagonist (rhuIL-IRa, anakinra) with a dramatic, rapid and sustained reduction in clinical inflammatory symptoms, reduction of serum amyloid A (an acute phase inflammatory reactant) and urinary excretion of amyloid.
  • rhuIL-IRa human interleukin-1 receptor antagonist
  • This treatment although effective, is limited in its use because it requires daily injection of the therapeutic agent.
  • Profound clinical improvement in response to anakinra may be an indicator that IL-1 is the key inflammatory cytokine underlying disease states, and indeed that such disease states are in fact autoinflammatory syndromes whose underlying genetic basis has yet to be determined. Examples include systemic-onset juvenile idiopathic arthritis (soJIA), also known as Still's disease, and the macrophage activation syndrome. The present invention also encompasses these indications.
  • the present invention describes the use of inhibitors of ICE/caspase-1, whether selective for ICE/caspase-1, or broadly active on a range of other caspases (2-14).
  • This treatment by inhibiting ICE and inhibiting IL-1 ⁇ production will reduce the symptoms and other disease conditions of MWS, FCAS, FMF, CINCAS, NOMID, TRAPS, HIDS and other autoinflammatory diseases, conditions or syndromes.
  • anakinra has been shown to be effective in treating Muckle-Wells syndrome, Familial Cold Autoinflammatory Syndrome, Hyper-IgD syndrome and systemic onset Juvenile idiopathic Arthritis, anakinra is a protein and it therefore does not possess ideal pharmaceutical properties. . Therefore, there is a need for small molecule, orally-active ICE inhibitors for treating certain diseases. Such compounds would be extremely useful in treating the aforementioned disease states where ICE plays a role.
  • the present invention relates to compounds for treating certain diseases associated with autoinflammatory diseases (sometimes referred to as autoinflammatory fever syndromes), Cryopyrin-associated Periodic Syndromes, and related syndromes such as Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS) (also known as Familial Cold Urticaria or FCU), Familial Mediterranean Fever (FMF), Chronic Infantile Neurological Cutaneous and Articular Syndrome (CINCAS), a.k.a. Neonatal Onset Multisystem Inflammatory Disease (NOMID), TNFR1-Associated Periodic Syndrome (TRAPS), Hyper-IgD periodic fever Syndrome (HIDS), and Blau's syndrome.
  • the invention also relates to compounds for treating certain diseases exhibiting profound clinical improvement in response to anakinra.
  • the invention also relates to methods for treating the above diseases.
  • the invention also relates to methods for identifying agents useful for treating these diseases.
  • FIGS. 1A-1C depict the in vitro inhibition by compound 7 of IL-1 ⁇ and IL-18 production by whole blood from patients with FCAS compared with healthy volunteers. See Example 18.
  • FIG. 2 depicts the in vitro inhibition by compound 7 of IL-1 ⁇ production by whole blood from patients with MWS. See Example 19.
  • FIGS. 3A-3C depict the clinical response of MWS patients to 14-day treatment with 900 mg compound 7 administered three times daily.
  • serum interleukin-18 was reduced on average by 55% at day 14.
  • serum acute phase reactant proteins serum amyloid A (SAA) and C-reactive protein (CRP) was reduced on average by 75% and 65%, respectively.
  • SAA serum amyloid A
  • CRP C-reactive protein
  • self-reported patient total symptoms were reduced on average by 60% during treatment. See Example 21.
  • This invention provides compounds disclosed herein and pharmaceutically acceptable derivatives thereof that are particularly effective for ameliorating, treating and/or preventing certain diseases associated with autoinflammatory syndromes and related syndromes, including, but not limited to, Muckle-Wells Syndrome (MWS), Familial Cold Autoinflamammatory Syndrome (FCAS) (also known as Familial Cold Urticaria or FCU), Familial Mediterranean Fever (FMF), Chronic Infantile Neurological Cutaneous and Articular Syndrome (CINCAS), a.k.a.
  • MFS Muckle-Wells Syndrome
  • FCAS Familial Cold Autoinflamammatory Syndrome
  • FMF Familial Mediterranean Fever
  • CINCAS Chronic Infantile Neurological Cutaneous and Articular Syndrome
  • Neonatal Onset Multisystem Inflammatory Disease NOMID
  • TNFR1-Associated Periodic Syndrome TRAPS
  • Hyper-IgD periodic fever Syndrome HIDS
  • Blau's syndrome systemic onset juvenile idiopathic arthritis (also known as Still's disease) and macrophage activation syndrome.
  • Symptoms associated with these diseases include, but are not limited to fever, urticaria, arthritis, serositis, systemic amyloidosis, a robust acute phase response, and a prominent neutrophilia in affected tissues.
  • the compounds according to this invention may be used to treat these disease states in mammals. Any compound that inhibits ICE may be used in the methods and compositions of this invention. Such compounds include those compounds that inhibit ICE selectively and those that inhibit one or more enzyme in the caspase or ICE/CED-3 family.
  • the compounds of this invention inhibit ICE and/or decrease IL-1, particularly IL-1 ⁇ and IL-18 levels. These compounds can be assayed, for example, for their ability to inhibit ICE, the production of IL-1 ⁇ and/or IL-18, the regulation of IL-1 and/or IL-18 levels, and/or affect IL-1 ⁇ and/or IL-18 activity. Assays for testing each of these activities are known in the art (see Examples herein, WO 95/35308 , WO 97/22619 , WO 99/47545 , or WO 01/90063 ). Accordingly, these compounds are capable of targeting and inhibiting events in the ICE and/or IL-1 mediated diseases set forth herein.
  • compounds for use in this invention include those of WO 00/55114 , WO 00/55127 , WO 00/61542 , WO.00/61542 , WO 01/05772 , WO 01/10383 , WO 01/16093 , WO 01/42216 , WO 01/72707 , WO 01/90070 , WO 01/94351 , US Publication 2003/0092703 , WO 02/094263 , US Publication 2002/0169177 , US Patent 6,184,210 , US Patent 6,184,244 , US Patent 6,187,771 , US Patent 6,197,750 , US Patent 6,242,422 , April 2001 American Chemical Society (ACS) meeting in San Diego, California, USA, w0 02/22611 , US Publication 2002/0058630 , US Publication 2003/0096737 , WO 95/35308 , WO 97/22619 , WO 99/47545 , and WO 01/
  • compounds for use in this invention include those of WO 04/058718 , WO 04/002961 , WO 95/35308 , WO 97/ 22619 , WO 99/47545 , and WO 01/ 90063 .
  • compounds for use in this invention include those of WO 95,135308 , WO 97/22619 , WO 99/47545 , and WO 01/90063 .
  • Preferred compounds are those recited in the claims herein. These compounds may be obtained by methods known to skilled practitioners and the methods disclosed in documents cited herein.
  • compositions and methods of this invention will be useful for controlling the levels of IL-1 ⁇ , IL-18 and other biomarkers and/or activity in vitro or in vivo .
  • the compositions and methods of this invention will thus be useful for controlling the levels of IL-1 ⁇ , IL-18 and other biomarkers in vivo and for treating or reducing the advancement, severity or effects of certain conditions, including diseases, disorders, or effects as set forth herein.
  • the invention provides a composition
  • a composition comprising a compound of this invention or a pharmaceutically acceptable derivative (e.g., salt) thereof, as described above, and a pharmaceutically acceptable carrier.
  • compositions of this invention may further comprise another therapeutic agent.
  • agents include, but are not limited to, a thrombolytic agents such as tissue plasminogen activator and streptokinase, an anti-inflammatory agent, a matrix metalloprotease inhibitor, a lipoxygenase inhibitor, a cytokine antagonist, (including, but not limited to, an antibody or binding protein against TNF, IL-1, IL-6, IL-12, IL-18 or their receptors), a chemokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine (including, but not limited to, the interleukin-1 receptor antagonist or anakinra), a growth factor, an immunomodulator (e.g., bropirimine, anti-human alpha interferon antibody, IL-2, GM-CSF, methionine enkephalin, interferon alpha, diethyldithiocarbamate, tumor necrosis factor,
  • pharmaceutically acceptable carrier refers to a non-toxic carrier that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof.
  • compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glycer
  • compositions comprising only a compound of this invention as the active component
  • methods for administering these compositions may additionally comprise the step of administering to the subject an additional agent.
  • agents include, but are not limited to, a thrombolytic agent such as tissue plasminogen activator and streptokinase, an anti-inflammatory agent, a matrix metalloprotease inhibitor, a lipoxygenase inhibitor, a cytokine antagonist (including, but not limited to, an antibody or binding protein against TNF, IL-1, IL-6, IL-12, IL-18 or their receptors), a chemokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine (including, but not limited to, the interleukin-1 receptor antagonist or anakinra), a growth factor, an immunomodulator (e.g., bropirimine, anti-human alpha interferon antibody, IL-2, GM-CSF, methionine enkephalin, interfer
  • the amount of compound present in the above-described compositions should be sufficient to cause a detectable decrease in the severity of the disease, or in ICE inhibition, the levels of IL-1 ⁇ , IL-18 or other biomarkers, or the activity of IL-1 ⁇ , IL-18 or other biomarkers.
  • salts of the compounds of this invention are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pec
  • Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such
  • compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, or central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and/or alter rate of excretion.
  • compositions of this invention are formulated for pharmaceutical administration to a subject or patient, e.g., a mammal, preferably a human being.
  • Such pharmaceutical compositions are used to ameliorate, treat or prevent autoinflammatory diseases in a subject and comprise a compound that inhibits ICE and a phramaceutically acceptable carrier.
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection and infusion techniques.
  • the compositions are administered orally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil and castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • the preparation can be in tablet form, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge.
  • the amount of solid carrier will vary, e.g., from about 25 to 800 mg, preferably about 25 mg to 400 mg.
  • the preparation can be, e.g., in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
  • any routine encapsulation is suitable, for example, using the aforementioned carriers in a hard gelatin capsule shell.
  • a syrup formulation can consist of a suspension or solution of the compound in a liquid carrier for example, ethanol, glycerin, or water with a flavoring or coloring agent.
  • An aerosol preparation can consist of a solution or suspension of the compound in a liquid carrier such as water, ethanol or glycerin; whereas in a powder dry aerosol, the preparation can include e.g., a wetting agent.
  • Formulations of the present invention comprise an active ingredient together with one or more acceptable carrier(s) thereof and optionally any other therapeutic ingredient(s).
  • the carrier(s) should be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions or solutions.
  • carriers that are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents known in the art.
  • the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration, and other well-known variables.
  • Such certain diseases include autoinflammatory syndromes such as cryopyrin-associated Periodic Syndromes, (including Muckle-Wells syndrome, Familial Cold Autoinflammatory Syndrome (FCAS, also known as Familial Cold Urticaria or FCU), chronic infantile neurological cutaneous and articular syndrome (a.k.a. neonatal onset multisystem Inflammatory disease)), familial mediterranean fever, TNFR1-Associated Periodic Syndrome (TRAPS), Hyper-IgD periodic fever Syndrome (HIDS), and Blau's syndrome.
  • FCAS Familial Cold Autoinflammatory Syndrome
  • FCU Familial Cold Urticaria or FCU
  • Chronic infantile neurological cutaneous and articular syndrome a.k.a. neonatal onset multisystem Inflammatory disease
  • familial mediterranean fever a.k.a. neona. neonatal onset multisystem Inflammatory disease
  • TRAPS TNFR1-Associated Periodic Syndrome
  • HIDS Hyper-IgD periodic fever Syndrome
  • Blau's syndrome Other autoinflammatory syndrome
  • the compounds of this invention can inhibit the release of IL-1, particularly IL-1 ⁇ and IL-18, and thus can be useful for inhibiting or blocking several pathophysiological effects of certain diseases as set forth herein.
  • This invention also relates to a therapeutic method for treating certain diseases, specifically autoinflammatory diseases, by (1) inhibiting IL-1, particularly IL-1 ⁇ and IL-18 release from cells and/or (2) preventing the untoward, toxic or lethal effects of excessively high tissue levels of IL-1, particularly IL-1 ⁇ and IL-18 in a mammal, including a human.
  • This method comprises administering to a mammal an effective ICE inhibiting quantity of one or more ICE/CED-3 inhibitors.
  • This method also can be used for the prophylactic treatment or prevention of certain diseases amenable thereto, including Muckle-Wells Syndrome (MWS), Familial autoinflammatory fever syndromes and related syndromes such as Cryopyrin-associated Periodic Syndromes, Cold Autoinflammatory Syndrome (FCAS, also known as Familial Cold Urticaria or FCU), Familial Mediterranean Fever (FMF), Chronic Infantile Neurological Cutaneous and Articular Syndrome (CINCAS), a.k.a. Neonatal Onset Multisystem Inflammatory Disease (NOMID), TNFRI-Associated Periodic Syndrome (TRAPS), Hyper-IgD periodic fever Syndrome (HIDS), Blau's syndrome, systemic onset juvenile idiopathic arthritis, Still's disease and macrophage activation syndrome.
  • the invention provides a method for the treating these disorders by administering to a mammal, including a human, in need thereof an effective amount of such compounds.
  • the compounds by inhibiting ICE and blocking the release of IL-1, particularly IL-1 ⁇ and IL-18 or decreasing IL-1, particularly IL-1 ⁇ and IL-18 levels and activity, as well as the pathophysiologic actions of excessive levels of IL-1, particularly IL-1 ⁇ and IL-18 in each of these circumstances, directly facilitate the arrest or resolution of certain diseases, and facilitates the restoration of normal function. Together, these actions relate their novel use in treating certain diseases.
  • ICE inhibition may be measured by methods known in the art and as described more fully herein.
  • the compounds may be useful in inhibiting the release of IL-1, particularly IL-1 ⁇ , and IL-18 release by monocytes, macrophages, neuronal cells, endothelial cells, epidermal cells, mesenchymal cells (for example: fibroblasts, skeletal myocytes, smooth muscle myocytes, cardiac myocytes) and many other types of cells.
  • condition or "state” refers to any disease, disorder, or effect that produces deleterious biological consequences in a subject.
  • the level of IL-1, particularly IL-1 ⁇ , and IL-18 protein in the blood or cell of a patient or a cell culture can be determined by for example, assaying for immunospecific binding to IL-1 ⁇ or IL-18 or to other proteins known to be produced as a result of the presence of active IL-1 ⁇ and IL-18, including, but not limited to, IL-1 ⁇ .
  • assaying for immunospecific binding to IL-1 ⁇ or IL-18 or to other proteins known to be produced as a result of the presence of active IL-1 ⁇ and IL-18, including, but not limited to, IL-1 ⁇ Such methods are known in the art.
  • immunoassays which can be used include, but are not limited to competitive and non-competitive assay systems, western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and FACS analysis with labeled antibodies.
  • assays well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York , which is incorporated by reference herein in its entirety).
  • IL-1 can also be used to determine the level of IL-1. particularly IL-1 ⁇ , and IL-18.
  • a competitive binding assay is a radioimmunoassay comprising the incubation of labeled proteins from cells expressing IL-1, particularly IL-1 ⁇ , and IL-18 (e.g., 3 H or 125 I) with an IL-1 ⁇ or IL-18 antibody in the presence of increasing amounts of unlabeled IL-1 ⁇ or IL-18, and the detection of the IL-1 ⁇ or IL-18 antibody bound to the labeled IL-1 ⁇ or IL-18.
  • the affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by Scatchard plot analysis.
  • Competition with a second antibody can also be determined using radioimmunoassays.
  • the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3 H or 125 I) in the presence of increasing amounts of an unlabeled second antibody.
  • a labeled compound e.g., 3 H or 125 I
  • IL-1 ⁇ or IL-18 levels can also be assayed by activity, for example, IL-1 levels can be assayed by a cell line that is capable of detecting bioactive levels of cytokines like IL-1 ⁇ or IL-18 or a growth factor.
  • the level of bioactive IL-1 ⁇ in a biological sample is detected by incubating a cell line genetically engineered with isopropyl- ⁇ -D-thiogalactopyranoside. The cell line is incubated with the sample to be tested and cell death in the cell line is monitored by determining the intensity of blue color, which is indicative of a bioactive cytokine or growth factor in the sample tested. See also, e.g., Burns (1994) 20(1):40-44 for IL-1 activity assay of serum of patients.
  • Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day and most preferably between about 1 and about 50 mg/kg body weight per day of the active ingredient compound are useful in a monotherapy.
  • dosage levels of between about 2 and about 200 mg/kg body weight per day, preferably between about 6 and about 100 mg/kg body weight per day and most preferably between about 25 and about 100 mg/kg body weight per day of the active ingredient compound are useful in a monotherapy.
  • an active ingredient compound of this invention is administered to a subject at a dose of between about 20 mg to about 10,000 mg per administration. In another embodiment, an active ingredient compound of this invention is administered to a subject at a dose of between about 300 mg to about 2,400 mg per administration. In yet another embodiment of this invention, an active ingredient compound of this invention is administered to a subject at a dose of between about 600 mg to about 1,800 mg per administration. In a preferred embodiment, a compound of this invention is administered to a subject at a dose of about 900 mg per administration.
  • the pharmaceutical compositions of this invention will be administered from about 1 to 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.
  • compositions of this invention comprise a combination of a compound of this invention and one or more additional therapeutic agents
  • both the compound and the additional agent should be present at dosage levels of between about 10% to abut 80% of the dosage normally administered in a monotherapy regime.
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to the desired level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence or disease symptoms.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of active ingredients will also depend upon the particular compound and other therapeutic agent, if present, in the composition.
  • a method for ameliorating, treating or preventing a disease of this invention in a subject comprises the step of administering to the subject any compound, pharmaceutical composition, or combination described herein.
  • the invention provides a method of treating a mammal, having one of the aforementioned diseases, comprising the step of administering to said mammal a pharmaceutically acceptable composition described above.
  • a pharmaceutically acceptable composition described above.
  • the patient if the patient is also administered another therapeutic agent, it may be delivered together with the compound of this invention in a single dosage form, or, as a separate dosage form.
  • the other therapeutic agent may be administered prior to, at the same time as, or following administration of a pharmaceutically acceptable composition comprising a compound of this invention.
  • the methods for identifying a compound or composition for treating a disease include methods for screening of a plurality of compounds or compositions for their ability to ameliorate the effects of certain disease(s) and/or improve the condition of a patient having certain disease(s) of this invention.
  • high throughput screening can be achieved by having cells in culture in a plurality of wells in a microtiter plate, adding a different compound or composition to each well and comparing the ICE inhibition and/or IL-1 levels and/or activity in each cell culture to the levels or activity present in a cell culture in a control well.
  • Controls that are useful for the comparison step according to this invention include cells or subjects that have not been treated with a compound or composition and cells or subjects have been treated with a compound or composition that is known to have no effect on ICE inhibition or activity.
  • the high throughput screening is automated so that the steps including the addition of the cells to the plate up to the data collection and analysis after addition of the compound or composition are done by machine.
  • Instruments that are useful in the comparison step of this invention e.g., instruments that can detect labeled objects (e.g., radiolabelled, fluorescent or colored objects) or objects that are themselves detectable, are commercially available and/or known in the art. Accordingly, compounds and compositions according to this invention that are useful for treating the certain disease disclosed herein can be quickly and efficiently screened.
  • a method for identifying a compound or composition for ameliorating, treating or preventing an autoinflammatory disease in a subject comprises administering to said subject a compound that inhibits ICE or a pharmaceutical composition comprising the compound and comparing the ICE inhibition in the subject before and after treatment with the compound.
  • this invention provides a method for identifying a compound or composition for ameliorating, treating or preventing an autoinflammatory disease in a subject which comprises administering to said subject a compound that inhibits ICE or a pharmaceutical composition comprising the compound and comparing a biomarker for autoinflammatory diseases in said subject before and after treatment with said compound.
  • biomarker is a physical, functional, or biochemical indicator, e.g., the presence of a particular metabolite, of a physiological or disease process.
  • certain biomarkers of inflammation may be used to evaluate the response of patients having autoinflammatory diseases listed herein to compounds that inhibit ICE.
  • These inflammatory biomarkers include, but are not limited to, interleukin-1, interleukin-6 (all autoinflammatory diseases), interleukin-8 (all autoinflammatory diseases), interleukin-18, serum amyloid A, C-reactive protein, erythrocyte sedimentation rate (ESR), haptoglobin, TNFalpha, immmunoglobins (particularly IgD), ferritin, leukocyte counts, platelet counts and hemoglobin.
  • this invention also provides a method for reduction of IL-1 ⁇ , IL-18 or other biomarker in a subject having an autoinflammatory disease comprising the step of administering to said subject a compound that inhibits ICE or a pharmaceutical composition comprising said compound.
  • the plasma concentration of the compound or composition in the subject is about equal to or greater than an IC 50 value taught according to this invention (see, e.g., Examples 18 and 19).
  • the plasma concentration of the compound or composition in the subject is between about 0.2 ⁇ M to about 50 ⁇ M, or about 0.8 ⁇ M to about 6 ⁇ M.
  • the reduction of -LL-1 ⁇ , IL-18 or other biomarker in a subject is measured by comparing (a) IL-1 ⁇ , IL-18 or other biomarker concentrations in said subject before or after treatment with said compound or composition to (b) IL-1 ⁇ , IL-18 or other biomarker concentrations in said subject during treatment with said compound or composition.
  • the percent reduction of IL-1 ⁇ , IL-18 or other biomarker in a subject is selected from the group consisting of (a) at least about 50% to about 100% reduction; (b) at least about 50% to about 90% reduction; and (c) at least about 60% to about 90% reduction.
  • Trifluoroacetic acid (5mL) was added to a stirred ice cold solution of [3S/R, (2S)]-5-fluoro-4-oxo-3- ⁇ [1-(phenothiazine-10-carbonyl)piperidine-2-carbonyl]amino ⁇ -pentanoic acid tert-butyl ester (130mg, 0.24mmol) in anhydrous DCM (5mL).
  • the mixture was stirred at 0°C for 0.5h then at room temperature for 0.5h.
  • the mixture was concentrated under reduced pressure and then the residue was dissolved in dry DCM. This process was repeated several times in order to remove excess trifluoroacetic acid.
  • reaction mixture was then allowed to stir for a further 3.5h at -78°C after which it was diluted with NH 4 Cl solution, diluted with ethyl acetate and washed sequentially with NaHCO 3 solution and brine.
  • the organic phase was dried (Na 2 SO 4 ) and concentrated to give a gum.
  • the resulting mixture was kept at 0°C for 3h, diluted with DCM, and then washed sequentially with saturated aqueous sodium thiosulphate, NaHCO 3 solution and brine.
  • the organics were dried (Na 2 SO 4 ) and concentrated.
  • ICE Inhibition may be measured by methods known in the art.
  • Blood samples are collected from patients with MWS, FCU, FMF, CINCAS, NOMID, TRAPS, HIDS, systemic onset Juvenile Idiopathic Arthritis, Still's disease and Macrophage Activation Syndrome or other autoinflammatory disease or condition and cultured in vitro as whole blood or processed for the preparation of peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • the production of IL-1 ⁇ is evaluated under normal, unstimulated conditions or in the presence of a stimulus such as lipopolysaccharide, Staphylococcus atreus, nigericin or phorbol myristate.
  • ICE inhibitors are added to the cultures at concentrations of 1-100,000 nM to demonstrate their ability to inhibit the production of IL-1 ⁇ and/or IL-18 by cells from patients with MWS, FCU, FMF, CINCAS, NOMID, TRAPS, HIDS, systemic onset Juvenile Idiopathic Arthritis, Still's disease and Macrophage Activation Syndrome or other autoinflammatory disease, condition or syndrome.
  • Patients with MWS, FCU, FMF, CINCAS, NOMID, TRAPS, HIDS, systemic onset Juvenile Idiopathic Arthritis, Still's disease and Macrophage Activation Syndrome or other autoinflammatory disease or condition are enrolled into a clinical trial to receive treatment with an ICE inhibitor.
  • the drug is administered at a dose of 10-10,000 mg by an appropriate route (oral, intravenous, subcutaneous, etc.) at a dosing frequency of 1-4 times/day or as needed to control the symptoms and other manifestations of the disease, condition or syndrome.
  • Treatment duration may range from periodic use of one or more days to daily use over the life-time of the patient.
  • the efficacy is demonstrated by virtue of their ability to reduce the clinical signs and symptoms, such as fever, urticaria, arthralgia, serositis, systemic amyloidosis, robust acute phase response and prominent neutrophilia in affected tissues.
  • Cryopyrin the protein encoded by the CAIS1 gene that is mutated in FGAS, modulates ICE/caspase-1 activation and its processing of pro-IL-1 ⁇ to active IL-1 ⁇ , as well as pro-IL-18 to active IL-18. It may be expected that the mutated cryopyrin protein would interact differently with ICE/caspase-1 and could alter the ICE/caspase-1 confirmation in a way that would alter the interaction of the ICE inhibitor compound with ICE/caspase-1, thus reducing the ability to the compound to inhibit ICE activation and IL-1 ⁇ and I1-18 processing. Therefore, the experiments of this example were conducted to confirm that compound 7 is able to inhibit ICE in cells of FCAS patients.
  • IL-1 ⁇ was evaluated under normal, unstimulated conditions and in the presence of lipopolysaccharide at a range of concentrations from 10-10,000 ng/mL.
  • Compound 7 was added to the cultures at concentrations of 30-30,000 nM to observe its ability to inhibit the production of IL-1 ⁇ and IL-18 by cells from patients with FCAS or healthy volunteer.
  • Figure 1 illustrates the results of these experiments.
  • PBMCs from FCAS patients and normal controls were incubated with 10 ng/ml LPS in the presence of increasing concentrations of compound 7 (0.03-30 ⁇ M) for 24 hours.
  • IL-1 ⁇ in cell culture media was measured by ELISA and the results for each subject were normalized to the level of IL-1 ⁇ release in the absence of compound 7. Results were reported in mean ⁇ SEM, for 3 FCAS patients and 5 control patients. LPS-stimulated IL-1 ⁇ was inhibited by compound 7 with potency very similar to that of PBMCs from normal subjects (IC 50 value ⁇ 1 ⁇ M).
  • Figure 1B illustrates the release of IL-1 ⁇ by PBMCs from FCAS patients or control subjects after exposure to LPS for 24 hours in the absence or presence of 10 ⁇ M compound 7. Results were reported in mean ⁇ SEM for 7 FCAS patients and 5 control patients. LPS stimulated greater amounts of IL-1 ⁇ release by PBMCs from FCAS patients than normal subjects and FCAS PBMCs responded to lower concentrations of LPS. Nevertheless, LPS-stimulated IL-1 ⁇ was inhibited by 10 ⁇ M of compound 7 similar to that of PBMCs from normal subjects.
  • Figure 1C illustrates the release of IL-18 by PBMCs from FCAS patients or control subjects after 24 hrs exposure to LPS in the absence or presence of 10 ⁇ M compound °7. Results were reported in mean ⁇ SEM for 3 FCAS patients and 3 control patients. LPS stimulated greater amounts of IL-18 release by PBMCs from FCAS patients than normal subjects and FCAS PBMCs responded to lower concentrations of LPS. Nevertheless, LPS-stimulated IL-18 was inhibited by 10 ⁇ M compound 7 to a similar extent as that of PBMCs from normal subjects.
  • Example 18 it may be expected that the mutated cryopyrin protein would interact differently with ICE/caspase-1 and could alter the ICE/caspase-1 conformation in a way that would alter the interaction of the ICE inhibitor compound with ICE/caspase-1, thus reducing the ability to the compound to inhibit ICE activation and IL-1 ⁇ and I1-18 processing. Therefore, the experiments of this example were conducted to confirm that compound 7 is able to inhibit ICE in cells of MWS patients.
  • IL-1 ⁇ in cell culture media was measured by ELISA and the results for each subject were normalized to the level of IL-1 ⁇ release in the absence of compound 7. Results were reported individually for each of the 4 MWS patients LPS-stimulated IL-1 ⁇ release by PBMCs from MWS patients was inhibited by compound 7 with potency similar to that of PBMCs from normal subjects (as observed in example 18). This indicates that the cryopyrin mutation in these MWS patients does not alter the ICE/caspase-1 activation in a way that it alters the potency of the interaction of the active metabolite (compound 8) of compound 7 with ICE/caspase-1.
  • composition of compound 7 tablets used in Example 21 below is provided in Table 1.
  • the drug product was formulated to provide 300 mg of compound 7 per tablet.
  • Table 1 Composition of Compound 7 300 mg Tablets Component Quantity (mg/tablet) Function
  • Compound 7 300 Active Ingredient Microcrystalline Cellulose (NF) 277.50 Filler Pregelatinized Starch (NF) 131.25 Disintegrant Sodium Starch Glycolate (NF) 15.00 Disintegrant Colloidal Silicon Dioxide (NF) 11.25 Glidant Talc (USP) 7.50 Glidant Magnesium Stearate (NF) 7.50 Lubricant Total 750
  • Compound 7 was administered orally at a dose of 900 mg 3 times daily for 14 days.
  • the anti-inflammatory activity of compound 7 in MWS patients was demonstrated by marked reduction in levels of serum interleukin-18, amyloid A and C-reactive protein during the period of treatment (see Figure 3 ).
  • the clinical efficacy of compound 7 was demonstrated by virtue of the reduction in the clinical symptoms reported by the patients, illustrated in Figure 3 as the sum total of symptoms including rash, fever/chills, arthralgia/myalgia, eye discomfort, fatigue (see Figure 3 ).
  • Compound 7 was also well tolerated by the four patients during the 14-day treatment period.
  • IL-18 serum interleukin-18
  • Baseline levels of serum IL-18 were 170-370 pg/mL and were only slightly elevated relative to those typically observed in healthy control subjects.
  • Serum amyloid A (SAA) and C-reactive protein (CRP) were measured before, during and after treatment with compound 7, and the amounts of SAA and CRP were reduced on average by 75% and 65%, respectively.
  • Baseline levels of SAA were 150-650 mg/L and of CRP were 20-90 mg/L, both considerably elevated relative to healthy control subjects.
  • Figure 3C illustrates that the self-reported patient total symptom scores were reduced on average by 60% during treatment.
  • Individual symptoms rash, fever/chills, arthralgia/myalgia, eye discomfort, fatigue
  • the total score was calculated as the sum of individual symptom scores (range 0-20).
  • Patients were experiencing mild-moderate symptoms at the beginning of treatment (scores 10-15), which were reduced to a minimal level (scores about 5) during treatment with compound 7.
  • an ICE/caspase-1 inhibitor, compound 7 is effective and beneficial in the treatment of an autoinflammatory disease, specifically Muckle-Wells Syndrome, since administration of compound 7 decreases markers of inflammation, including serum interleukin-18, serum amyloid A and serum C-reactive protein and reduces the symptoms of MWS experienced by the patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP10178054A 2004-05-27 2005-05-27 Traitement de maladies autoinflammatoires a l'aide d'inhibiteurs de l'ice Withdrawn EP2295054A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57499304P 2004-05-27 2004-05-27
EP05804856A EP1778221A2 (fr) 2004-05-27 2005-05-27 Traitement de maladies autoinflammatopires a l'aide d'inhibiteurs de l'ice

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP05804856.2 Division 2005-05-27

Publications (1)

Publication Number Publication Date
EP2295054A1 true EP2295054A1 (fr) 2011-03-16

Family

ID=35311316

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10178054A Withdrawn EP2295054A1 (fr) 2004-05-27 2005-05-27 Traitement de maladies autoinflammatoires a l'aide d'inhibiteurs de l'ice
EP05804856A Withdrawn EP1778221A2 (fr) 2004-05-27 2005-05-27 Traitement de maladies autoinflammatopires a l'aide d'inhibiteurs de l'ice

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05804856A Withdrawn EP1778221A2 (fr) 2004-05-27 2005-05-27 Traitement de maladies autoinflammatopires a l'aide d'inhibiteurs de l'ice

Country Status (7)

Country Link
US (2) US7531570B2 (fr)
EP (2) EP2295054A1 (fr)
JP (1) JP2008500374A (fr)
CN (1) CN1980658A (fr)
AU (1) AU2005249503B2 (fr)
CA (1) CA2567080A1 (fr)
WO (1) WO2005117846A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4594520B2 (ja) * 1998-03-19 2010-12-08 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼのインヒビター
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2005115362A1 (fr) * 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Traitement de crises epileptiques au moyen d'inhibiteurs ice
NO345888B1 (no) 2005-10-26 2021-09-27 Novartis Ag Medikament til bruk ved behandling av familiær Middelhavsfeber omfattende et humant IL-1-beta bindende antistoff og en farmasøytisk sammensetning omfattende antistoffet til bruk ved behandling av familiær Middelhavsfeber.
WO2008100217A1 (fr) * 2007-02-12 2008-08-21 Soederkvist Peter Polymorphismes des gènes de l'inflammasome cryopyrine et leurs utilisations dans le traitement des maladies inflammatoires
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
ES2552977T3 (es) * 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
WO2012061786A1 (fr) 2010-11-05 2012-05-10 Brandeis University Alpha-synucléine clivée ice en tant que marqueur biologique
CN103857288B (zh) 2011-03-04 2016-09-21 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的氨基-喹啉
US9956260B1 (en) * 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AU2014220300B2 (en) 2013-02-21 2016-10-13 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11084807B2 (en) 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
AU2017383127B2 (en) 2016-12-23 2024-08-15 Casp-Aid Inc. Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
FR3114741A1 (fr) * 2020-10-07 2022-04-08 Etienne Jacotot Traitements des infections à coronavirus, du syndrome de libération de cytokine, du syndrome de la tempête de cytokines ou des maladies associées à l'activation excessive des inflammasomes par l'utilisation d'inhibiteurs des caspases inflammatoires.
WO2022074134A1 (fr) * 2020-10-07 2022-04-14 Etienne Jacotot Traitements d'infections à coronavirus, de syndrome de libération de cytokines, de choc cytokinique, ou de maladies associées à l'activation excessive des inflammasomes par l'utilisation d'inhibiteurs des caspases inflammatoires

Citations (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005071A1 (fr) 1991-08-30 1993-03-18 Sterling Winthrop Inc. INTERLEUKINE 1β PROTEASE ET INHIBITEURS D'INTERLEUKINE 1β PROTEASE
WO1993009135A1 (fr) 1991-11-04 1993-05-13 Sandoz Ltd. Peptides inhibant la liberation d'il-1 beta
WO1995035308A1 (fr) 1994-06-17 1995-12-28 Vertex Pharmaceuticals Incorporated INHIBITEURS DE L'ENZYME DE CONVERSION D'INTERLEUKINE-1$g(b)
WO1997022619A2 (fr) 1995-12-20 1997-06-26 Vertex Pharmaceuticals Incorporated INHIBITEURS DE L'ENZYME CONVERTISSANT L'INTERLEUKINE-1$g(b)
WO1998010778A1 (fr) 1996-09-12 1998-03-19 Idun Pharmaceuticals, Inc. INHIBITION DE L'APOPTOSE AU MOYEN D'INHIBITEURS DE LA FAMILLE CED-3/ICE (ENZYME DE CONVERSION DE L'INTERLEUKINE-1β)
WO1998016502A1 (fr) 1996-10-11 1998-04-23 Warner-Lambert Company INHIBITEURS A BASE D'ESTER D'ASPARTATE DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
WO1998016504A2 (fr) 1996-10-11 1998-04-23 Warner-Lambert Company INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1β A BASE D'ACIDE ASPARTIQUE A SUBSTITUTION SULFONAMIDE
WO1998016505A1 (fr) 1996-10-11 1998-04-23 Warner-Lambert Company INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1β A BASE DE SULFONAMIDE
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
WO1999036426A1 (fr) 1998-01-20 1999-07-22 Warner-Lambert Company ALDEHYDE DE L'ACIDE N-[2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETOXYL]-L-ASPARTIQUE, INHIBITEUR in vivo DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
WO1999047154A1 (fr) 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptides inhibiteurs de caspase et leur utilisation
WO1999047545A2 (fr) 1998-03-19 1999-09-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspases
WO1999056765A1 (fr) 1998-05-05 1999-11-11 Warner-Lambert Company INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1$g(b)
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO2000055127A1 (fr) 1999-03-16 2000-09-21 Merck Frosst Canada & Co. Dipeptides de gamma-cetoacides agissant en tant qu'inhibiteurs de caspase-3
WO2000055114A1 (fr) 1999-03-16 2000-09-21 Cytovia, Inc. Inhibiteurs de caspases 2-aminobenzamidiques substitues et leur utilisation
WO2000061542A1 (fr) 1999-04-09 2000-10-19 Cytovia, Inc. Inhibiteurs de la caspase et leur utilisation
WO2001000658A1 (fr) 1999-03-02 2001-01-04 Idun Pharmaceuticals, Inc. 2-indolylcarbonyldipeptides (n-substitues) modifies c-terminal en tant qu'inhibiteurs de la famille ice/ced-3 de proteases a cysteine
WO2001005772A1 (fr) 1999-07-19 2001-01-25 Merck Frosst Canada & Co. Pyrazinones, compositions contenant ces composes
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6187771B1 (en) 1996-09-20 2001-02-13 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
WO2001010383A2 (fr) 1999-08-06 2001-02-15 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et leurs utiilsations
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
WO2001016093A1 (fr) 1999-08-27 2001-03-08 Cytovia, Inc. ACIDES α-HYDROXY SUBSTITUES INHIBITEURS DE CASPASES ET LEURS UTILISATIONS
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
WO2001042216A2 (fr) 1999-12-08 2001-06-14 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et utilisations correspondantes
WO2001072707A2 (fr) 2000-03-29 2001-10-04 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase du groupe carbamate et leur utilisation
WO2001083458A2 (fr) * 2000-05-04 2001-11-08 Vertex Pharmaceuticals Incorporated Synthese asymetrique de l'acide piperazique et de derives de cet acide
WO2001090070A2 (fr) 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Inhibiteurs de la caspase et leurs utilisations
WO2001090063A2 (fr) 2000-05-19 2001-11-29 Vertex Pharmaceuticals Incorporated Promedicament inhibiteur d'enzyme de conversion d'interleukine 1$g(b) (ice)
WO2001094351A1 (fr) 2000-06-07 2001-12-13 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et utilisations de ces inhibiteurs
WO2002012638A1 (fr) 2000-08-10 2002-02-14 Thermax International Corp. Système polyvalent d'injection de lait de ciment
WO2002022611A2 (fr) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et leurs utilisations
WO2002042278A2 (fr) 2000-11-21 2002-05-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase a base d'imidazole et de benzimidazole et utilisations associees
WO2002085899A1 (fr) 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyl-dicarbamides en tant qu'inhibiteurs de caspase
WO2002089749A2 (fr) 2001-05-10 2002-11-14 Abbott Gmbh & Co.Kg Ethers arylsulfonamide et techniques d'utilisation de ces composes
WO2002094263A2 (fr) 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et leurs utilisations
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
WO2003032918A2 (fr) 2001-10-16 2003-04-24 Idun Pharmaceuticals, Inc. Traitement d'une maladie infectieuse a l'aide d'inhibiteurs de la famille ced-3/ice (enzyme de conversion de l'interleukine-1 beta)
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
WO2003042169A2 (fr) 2001-10-09 2003-05-22 Vertex Pharmaceuticals Incorporated Procede de synthese de derives d'acide glutamique et d'acide aspartique specialement utiles en tant qu'intermediaires dans la production d'un inhibiteur de caspase
WO2003068242A1 (fr) 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipides tels que des promedicaments inhibiteurs de caspases
WO2003072528A2 (fr) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. Inhibiteurs de dipeptidyle d'acide substitue de la famille ice/ced-3 des proteases de cysteine
WO2003088917A2 (fr) 2002-04-19 2003-10-30 Vertex Pharmaceuticals Incorporated Regulation du tnf alpha
WO2003103677A1 (fr) 2002-06-10 2003-12-18 The Procter & Gamble Company Derives d'azepine et de thiazeran utilises comme inhibiteurs de enzyme de conversion de l'interleukine
WO2003104231A1 (fr) 2002-06-10 2003-12-18 The Procter & Gamble Company Nouveaux inhibiteurs d'enzymes de conversion de l'interleukine 1$g(b)
WO2003106460A1 (fr) 2002-06-17 2003-12-24 The Procter & Gamble Company Inhibiteurs d'enzyme de conversion d'interleukine-1 beta
WO2004002961A1 (fr) 2002-06-28 2004-01-08 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspases et leurs utilisations
WO2004002401A2 (fr) 2002-04-05 2004-01-08 Cytovia, Inc. Inhibiteurs de caspases pour le traitement de maladies et d'etats pathologiques dus a une exposition a des radionucleides, a des agents biologiques ou a des agents chimiques
WO2004058718A1 (fr) 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated Derives d'esters et d'amides d'acide 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoique et leur utilisation en tant qu'inhibiteurs de caspase
WO2005003100A2 (fr) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Composes et leur utilisation therapeutique
WO2005047906A1 (fr) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methodes de controle de l'il-18
WO2005085236A2 (fr) * 2004-02-27 2005-09-15 Vertex Pharmaceuticals Incorporated Inhibiteurs de la caspase et leurs utilisations

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US4465679A (en) 1983-01-31 1984-08-14 Usv Pharmaceutical Corporation 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof
IL72523A (en) 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5158936A (en) 1986-12-22 1992-10-27 Syntex (U.S.A.) Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5008245A (en) 1988-10-27 1991-04-16 University Of Kentucky Research Foundation Novel peptidyl carbamate inhibitors of the enzyme elastase
CA2021660A1 (fr) 1989-07-26 1991-01-27 Philippe Bey Inhibiteurs de la peptidose
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
AU7775991A (en) 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
EP0503561B1 (fr) 1991-03-15 1998-10-28 Hoechst Aktiengesellschaft Procédé pour l'accouplement diastereoselective reductif des alpha aminoaldehydes homochirales
DE69226820T2 (de) * 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
US5278061A (en) 1991-08-16 1994-01-11 Merck & Co., Inc. Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme
EP0533226A3 (en) 1991-08-16 1993-08-18 Merck & Co. Inc. Novel chromophore containing compounds
US6348570B1 (en) 1991-08-16 2002-02-19 Merck & Co., Inc. Chromophore containing compounds and their use in determining interleukin-1β convertase activity
EP0541946B1 (fr) 1991-10-07 1996-07-17 Hoechst Aktiengesellschaft Procédé de couplage-pinacol réductant diastéréosélectif d'alpha-aminoaldéhydes
EP0547699A1 (fr) 1991-12-19 1993-06-23 Merck & Co. Inc. Dérivés peptidiques comme inhibiteurs d'enzyme convertissant l'interleukine 1-bêta
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
DE69320176T2 (de) 1992-02-21 1999-04-08 Merck & Co., Inc., Rahway, N.J. Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms
WO1994000154A1 (fr) 1992-06-24 1994-01-06 Merck & Co., Inc. ADN CODANT L'ENZYME DE CONVERSION DU PRECURSEUR DE L'INTERLEUKINE 1$g(b)
CA2139854A1 (fr) 1992-07-31 1994-02-17 Ralph P. Robinson Derives de l'acide peptidyl-4-amino-2,2-difluoro-3-oxo-1,6-hexanedioique utilises comme agents anti-inflammatoires
CA2109646C (fr) 1992-11-24 2000-03-07 Gaston O. Daumy Peptides para-nitroanilides
EP0618223A3 (fr) 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibent la libération d'interleukine 1-bêta utiles comme agents antiinflammatoires.
CA2122227A1 (fr) 1993-04-29 1994-10-30 Roland E. Dolle Analogues de peptides utilises comme inhibiteurs irreversibles de la protease de l'interleukine-1.beta.
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
US5411985A (en) 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (ja) 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
ATE170868T1 (de) 1993-06-04 1998-09-15 Vertex Pharma Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
US5866545A (en) 1993-08-13 1999-02-02 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
EP0752987B1 (fr) 1994-03-31 2003-11-12 Vertex Pharmaceuticals Incorporated Derives du pyrimidinyle inhibiteurs de l'interleukine
CA2189036A1 (fr) 1994-04-29 1995-11-09 Roland E. Dolle Amides d'halomethyle utilisees comme inhibiteurs de l'il-1.beta. protease.
US5492824A (en) 1994-05-12 1996-02-20 Basf Ag Ice and ice-like compositions and methods of making same
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US6057119A (en) 1994-06-17 2000-05-02 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
TW394764B (en) 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
CA2215211A1 (fr) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Inhibiteur de la protease de cysteine
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
WO1997008174A1 (fr) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Enzyme de conversion d'interleukine et apoptose
EP0851760A4 (fr) 1995-08-31 1998-11-25 Smithkline Beecham Corp Enzyme de conversion d'interleukines et apoptose
EP0761680A3 (fr) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Composés de tétrazole ayant une activité inhibante d'enzyme convertissant l'Interleukine-1bêta
WO1997024339A1 (fr) 1995-12-27 1997-07-10 Ono Pharmaceutical Co., Ltd. Derives de tetrazole et medicaments les contenant a titre d'ingredients actifs
US5869519A (en) 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
CN101524351A (zh) 2003-12-01 2009-09-09 沃泰克斯药物股份有限公司 使用ice抑制剂治疗感染疾病
WO2005115362A1 (fr) 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Traitement de crises epileptiques au moyen d'inhibiteurs ice
CA2568352C (fr) * 2004-06-04 2011-09-13 Regeneron Pharmaceuticals, Inc. Procedes d'utilisation d'antagonistes de l'il-1 dans le traitement de maladies auto-inflammatoires

Patent Citations (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600880A1 (fr) 1991-08-30 1994-06-15 Sanofi INTERLEUKINE 1$g(b) PROTEASE ET INHIBITEURS D'INTERLEUKINE 1$g(b) PROTEASE
EP1378573A1 (fr) 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukine 1-bêta protéase et inhibiteurs d'interleukine 1-bêta protéase
WO1993005071A1 (fr) 1991-08-30 1993-03-18 Sterling Winthrop Inc. INTERLEUKINE 1β PROTEASE ET INHIBITEURS D'INTERLEUKINE 1β PROTEASE
WO1993009135A1 (fr) 1991-11-04 1993-05-13 Sandoz Ltd. Peptides inhibant la liberation d'il-1 beta
WO1995035308A1 (fr) 1994-06-17 1995-12-28 Vertex Pharmaceuticals Incorporated INHIBITEURS DE L'ENZYME DE CONVERSION D'INTERLEUKINE-1$g(b)
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5932549A (en) 1995-09-12 1999-08-03 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1β converting enzyme inhibitory activity
WO1997022619A2 (fr) 1995-12-20 1997-06-26 Vertex Pharmaceuticals Incorporated INHIBITEURS DE L'ENZYME CONVERTISSANT L'INTERLEUKINE-1$g(b)
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6693096B2 (en) 1996-09-12 2004-02-17 Idun Pharmaceuticals, Inc. Treatment of inflammation-associated disorders using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
WO1998010778A1 (fr) 1996-09-12 1998-03-19 Idun Pharmaceuticals, Inc. INHIBITION DE L'APOPTOSE AU MOYEN D'INHIBITEURS DE LA FAMILLE CED-3/ICE (ENZYME DE CONVERSION DE L'INTERLEUKINE-1β)
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6528506B2 (en) 1996-09-12 2003-03-04 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6187771B1 (en) 1996-09-20 2001-02-13 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
WO1998016502A1 (fr) 1996-10-11 1998-04-23 Warner-Lambert Company INHIBITEURS A BASE D'ESTER D'ASPARTATE DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
EP0932600A2 (fr) 1996-10-11 1999-08-04 Warner-Lambert Company INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1$g(b) A BASE D'ACIDE ASPARTIQUE A SUBSTITUTION SULFONAMIDE
US6083981A (en) 1996-10-11 2000-07-04 Warner-Lambert Company Sulfonamide substituted aspartic acid interleukin-1β converting enzyme inhibitors
EP0932598A1 (fr) 1996-10-11 1999-08-04 Warner-Lambert Company INHIBITEURS A BASE D'ESTER D'ASPARTATE DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
US6316415B1 (en) 1996-10-11 2001-11-13 Basf Aktiengesellschaft Sulfonamide interleukin-1β converting enzyme inhibitors
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
WO1998016505A1 (fr) 1996-10-11 1998-04-23 Warner-Lambert Company INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1β A BASE DE SULFONAMIDE
WO1998016504A2 (fr) 1996-10-11 1998-04-23 Warner-Lambert Company INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1β A BASE D'ACIDE ASPARTIQUE A SUBSTITUTION SULFONAMIDE
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
WO1999036426A1 (fr) 1998-01-20 1999-07-22 Warner-Lambert Company ALDEHYDE DE L'ACIDE N-[2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETOXYL]-L-ASPARTIQUE, INHIBITEUR in vivo DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
EP1049703A1 (fr) 1998-01-20 2000-11-08 Warner-Lambert Company ALDEHYDE DE L'ACIDE N- 2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETOXYL]-L-ASPARTIQUE, INHIBITEUR $i(in vivo) DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
US6153591A (en) 1998-03-16 2000-11-28 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
WO1999047154A1 (fr) 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptides inhibiteurs de caspase et leur utilisation
WO1999047545A2 (fr) 1998-03-19 1999-09-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspases
WO1999056765A1 (fr) 1998-05-05 1999-11-11 Warner-Lambert Company INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1$g(b)
EP1082127A1 (fr) 1998-05-05 2001-03-14 Warner-Lambert Company INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1$g(b)
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
WO2001000658A1 (fr) 1999-03-02 2001-01-04 Idun Pharmaceuticals, Inc. 2-indolylcarbonyldipeptides (n-substitues) modifies c-terminal en tant qu'inhibiteurs de la famille ice/ced-3 de proteases a cysteine
WO2000055127A1 (fr) 1999-03-16 2000-09-21 Merck Frosst Canada & Co. Dipeptides de gamma-cetoacides agissant en tant qu'inhibiteurs de caspase-3
WO2000055114A1 (fr) 1999-03-16 2000-09-21 Cytovia, Inc. Inhibiteurs de caspases 2-aminobenzamidiques substitues et leur utilisation
US6620782B1 (en) 1999-03-16 2003-09-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6716818B2 (en) 1999-04-09 2004-04-06 Cytovia, Inc. Caspase inhibitors and the use thereof
WO2000061542A1 (fr) 1999-04-09 2000-10-19 Cytovia, Inc. Inhibiteurs de la caspase et leur utilisation
US6355618B1 (en) 1999-04-09 2002-03-12 Cytovia, Inc. Caspase inhibitors and the use thereof
WO2001005772A1 (fr) 1999-07-19 2001-01-25 Merck Frosst Canada & Co. Pyrazinones, compositions contenant ces composes
WO2001010383A2 (fr) 1999-08-06 2001-02-15 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et leurs utiilsations
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
WO2001016093A1 (fr) 1999-08-27 2001-03-08 Cytovia, Inc. ACIDES α-HYDROXY SUBSTITUES INHIBITEURS DE CASPASES ET LEURS UTILISATIONS
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
WO2001042216A2 (fr) 1999-12-08 2001-06-14 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et utilisations correspondantes
WO2001072707A2 (fr) 2000-03-29 2001-10-04 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase du groupe carbamate et leur utilisation
WO2001083458A2 (fr) * 2000-05-04 2001-11-08 Vertex Pharmaceuticals Incorporated Synthese asymetrique de l'acide piperazique et de derives de cet acide
WO2001090063A2 (fr) 2000-05-19 2001-11-29 Vertex Pharmaceuticals Incorporated Promedicament inhibiteur d'enzyme de conversion d'interleukine 1$g(b) (ice)
WO2001090070A2 (fr) 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Inhibiteurs de la caspase et leurs utilisations
WO2001094351A1 (fr) 2000-06-07 2001-12-13 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et utilisations de ces inhibiteurs
WO2002012638A1 (fr) 2000-08-10 2002-02-14 Thermax International Corp. Système polyvalent d'injection de lait de ciment
US20020058630A1 (en) 2000-09-13 2002-05-16 Jean-Damien Charrier Caspase inhibitors and uses thereof
WO2002022611A2 (fr) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et leurs utilisations
WO2002042278A2 (fr) 2000-11-21 2002-05-30 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase a base d'imidazole et de benzimidazole et utilisations associees
US20020169177A1 (en) 2000-11-21 2002-11-14 David Kay Imidazole and benzimidazole caspase inhibitors and uses thereof
WO2002085899A1 (fr) 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyl-dicarbamides en tant qu'inhibiteurs de caspase
US20030096737A1 (en) 2001-04-19 2003-05-22 Anita Diu-Hercend Caspase inhibitors and uses thereof
WO2002089749A2 (fr) 2001-05-10 2002-11-14 Abbott Gmbh & Co.Kg Ethers arylsulfonamide et techniques d'utilisation de ces composes
US20030092703A1 (en) 2001-05-23 2003-05-15 Michael Mortimore Caspase inhibitors and uses thereof
WO2002094263A2 (fr) 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspase et leurs utilisations
WO2003042169A2 (fr) 2001-10-09 2003-05-22 Vertex Pharmaceuticals Incorporated Procede de synthese de derives d'acide glutamique et d'acide aspartique specialement utiles en tant qu'intermediaires dans la production d'un inhibiteur de caspase
WO2003032918A2 (fr) 2001-10-16 2003-04-24 Idun Pharmaceuticals, Inc. Traitement d'une maladie infectieuse a l'aide d'inhibiteurs de la famille ced-3/ice (enzyme de conversion de l'interleukine-1 beta)
WO2003072528A2 (fr) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. Inhibiteurs de dipeptidyle d'acide substitue de la famille ice/ced-3 des proteases de cysteine
WO2003068242A1 (fr) 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipides tels que des promedicaments inhibiteurs de caspases
WO2004002401A2 (fr) 2002-04-05 2004-01-08 Cytovia, Inc. Inhibiteurs de caspases pour le traitement de maladies et d'etats pathologiques dus a une exposition a des radionucleides, a des agents biologiques ou a des agents chimiques
WO2003088917A2 (fr) 2002-04-19 2003-10-30 Vertex Pharmaceuticals Incorporated Regulation du tnf alpha
WO2003104231A1 (fr) 2002-06-10 2003-12-18 The Procter & Gamble Company Nouveaux inhibiteurs d'enzymes de conversion de l'interleukine 1$g(b)
US20040009966A1 (en) 2002-06-10 2004-01-15 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US20040014753A1 (en) 2002-06-10 2004-01-22 The Procter & Gamble Company Novel interleukin-1beta converting enzyme inhibitors
WO2003103677A1 (fr) 2002-06-10 2003-12-18 The Procter & Gamble Company Derives d'azepine et de thiazeran utilises comme inhibiteurs de enzyme de conversion de l'interleukine
US20030236296A1 (en) 2002-06-17 2003-12-25 The Procter & Gamble Company Novel interleukin-1beta converting enzyme inhibitors
WO2003106460A1 (fr) 2002-06-17 2003-12-24 The Procter & Gamble Company Inhibiteurs d'enzyme de conversion d'interleukine-1 beta
WO2004002961A1 (fr) 2002-06-28 2004-01-08 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspases et leurs utilisations
WO2004058718A1 (fr) 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated Derives d'esters et d'amides d'acide 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoique et leur utilisation en tant qu'inhibiteurs de caspase
WO2005003100A2 (fr) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Composes et leur utilisation therapeutique
WO2005047906A1 (fr) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methodes de controle de l'il-18
WO2005085236A2 (fr) * 2004-02-27 2005-09-15 Vertex Pharmaceuticals Incorporated Inhibiteurs de la caspase et leurs utilisations

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"INTERLEUKIN-1-RECEPTOR ANTAGONIST IN THE MUCKLE-WELLS SYNDROME", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 348, no. 25, 19 June 2003 (2003-06-19), pages 2583 - 2584, XP009054112, ISSN: 1533-4406 *
AUSUBEL ET AL,: "Current Protocols in Molecular Biology", vol. 1, 1994, JOHN WILEY & SONS, INC.
BURNS, vol. 20, no. 1, 1994, pages 40 - 44
CHARLES A. DINARELLO: "Unraveling the NALP-3/IL-1[beta] Inflammasome", IMMUNITY, vol. 20, no. 3, 1 March 2004 (2004-03-01), pages 243 - 244, XP055015940, ISSN: 1074-7613, DOI: 10.1016/S1074-7613(04)00055-X *
GRENIER J M ET AL: "Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 530, no. 1-3, 23 October 2002 (2002-10-23), pages 73 - 78, XP004388094, ISSN: 0014-5793 *
GUMUCIO ET AL., CLIN. EXP. RHEUMATOL., vol. 20, 2002, pages S-45 - S-53
HAWKINS P N ET AL: "Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 50, no. 2, February 2004 (2004-02-01), pages 607 - 612, XP002345728, ISSN: 0004-3591 *
HOFFMAN ET AL., NAT. GENET., vol. 29, 2001, pages 301 - 305
JOHNSTONE RF; DOLEN WK; HOFFMAN HM: "A large kindred with familial cold autoinflammatory syndrome", ANN ALLERGY ASTHMA IMMUNOL, vol. 90, no. 2, 2003, pages 233 - 7
LAETITIA AGOSTINI ET AL: "NALP3 Forms an IL-1[beta]-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder", IMMUNITY, vol. 20, no. 3, 1 March 2004 (2004-03-01), pages 319 - 325, XP055015939, ISSN: 1074-7613, DOI: 10.1016/S1074-7613(04)00046-9 *
NEVEN B; CALLEBAUT I; PRIEUR AM; FELDMANN J; BODEMER C; LEPORE L; DERFALVI B; BENJAPONPITAK S; VESELY R; SAUVAIN MJ: "Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU", BLOOD, vol. 103, no. 7, 2004, pages 2809 - 15

Also Published As

Publication number Publication date
EP1778221A2 (fr) 2007-05-02
US20090192094A1 (en) 2009-07-30
CN1980658A (zh) 2007-06-13
WO2005117846A2 (fr) 2005-12-15
AU2005249503A1 (en) 2005-12-15
AU2005249503B2 (en) 2011-08-25
WO2005117846A3 (fr) 2006-02-02
US20050267101A1 (en) 2005-12-01
JP2008500374A (ja) 2008-01-10
US7531570B2 (en) 2009-05-12
CA2567080A1 (fr) 2005-12-15

Similar Documents

Publication Publication Date Title
US20090192094A1 (en) Treatment of diseases using ice inhibitors
US7960398B2 (en) Regulation of TNF-alpha
EP1807083B1 (fr) Utilisation de pirlindole pour traiter des maladies caracterisees par une proliferation de lymphocytes t et/ou une hyperproliferation de keratinocytes, en particulier une dermatite atopique et un psoriasis
JP6953468B2 (ja) 新規の使用
JP2008539250A (ja) アテローム性動脈硬化症を処置するための方法
US20150190404A1 (en) Treating seizures using ice inhibitors
WO2001047558A1 (fr) Medicaments protegeant les nerfs
US20050233974A1 (en) Treating infectious diseases using ice inhibitors
JP2007538013A5 (fr)
JP2010111581A (ja) ドーパミンｄ２様受容体アゴニストを有効成分とする医薬及びスクリーニング方法
KR101190529B1 (ko) Ｉｃｅ 억제제를 사용하는 발작의 치료

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1778221

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17P Request for examination filed

Effective date: 20110913

17Q First examination report despatched

Effective date: 20120208

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1155372

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120619

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1155372

Country of ref document: HK